Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 1/20 | 0.38 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.37 |
| ▸ | PTGES | O14684 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 5/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.36 |
| ▸ | BTN3A1 | O00481 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14934182 | 1.00 | ITGA4 (0.38) | ITGA4ITGB7ALOX5PTGESMEN1 | |
| SCHEMBL18476530 | 1.00 | ITGA4 (0.38) | ITGA4ITGB7ALOX5PTGESMEN1 | |
| SCHEMBL14934096 | 0.92 | HTT (0.36) | ALDH1A1HTTBTN3A1 | |
| SCHEMBL30583779 | 0.90 | MEN1 (0.42) | ALOX5PTGESMEN1KMT2AALDH1A1 | |
| SCHEMBL16258631 | 0.90 | MEN1 (0.42) | ALOX5PTGESMEN1KMT2AALDH1A1 | |
| SCHEMBL16258629 | 0.90 | MEN1 (0.42) | ALOX5PTGESMEN1KMT2AALDH1A1 | |
| SCHEMBL30511498 | 0.89 | ALOX5 (0.41) | ALOX5PTGESMEN1KMT2AALDH1A1 | |
| SCHEMBL23843999 | 0.89 | ALDH1A1 (0.46) | ITGA4ITGB7MEN1KMT2AALDH1A1 | |
| SCHEMBL18476577 | 0.89 | ALDH1A1 (0.46) | ITGA4ITGB7MEN1KMT2AALDH1A1 | |
| SCHEMBL26276734 | 0.89 | ALDH1A1 (0.46) | ITGA4ITGB7MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12485135-B2 | Nicotinamide mononucleotide derivatives and their uses | METRO INTERNATIONAL BIOTECH, LLC (US) | 2025-12-02 | — | — | US | disclosed |
| US-20240350523-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | METROBIOTECH, LLC | 2024-10-24 | — | — | US | disclosed |
| US-11878027-B2 | Nicotinamide mononucleotide derivatives and their uses | METRO INTERNATIONAL BIOTECH, LLC (US) | 2024-01-23 | — | — | US | disclosed |
| US-20230158053-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | METROBIOTECH, LLC | 2023-05-25 | — | — | US | disclosed |
| US-11464796-B2 | Nicotinamide mononucleotide derivatives and their uses | METRO INTERNATIONAL BIOTECH, LLC (US) | 2022-10-11 | — | — | US | disclosed |
| US-20140286903-A1 | Substituted Purine Nucleosides, Phosphoramidate and Phosphordiamidate Derivatives for Treatment if Viral Infections | INHIBITEX, INC. (US) | 2014-09-25 | — | — | US | disclosed |
| WO-2013070887-A1 | SUBSTITUTED PURINE NUCLEOSIDES, PHOSPHORAMIDATE AND PHOSPHORDIAMIDATE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS | INHIBITEX, INC. (US) | 2013-05-16 | — | — | WO | disclosed |
| WO-2013066991-A1 | CRYSTALLINE SOLVATES OF NUCLEOSIDE PHOSPHOROAMIDATES, THEIR STEREOSELECTIVE PREPARATION, NOVEL INTERMEDIATES THEREOF, AND THEIR USE IN THE TREATMENT OF VIRAL DISEASE | INHIBITEX, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158053-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | NAMPT, NNT, NQO1 | ITGA4 3379/4885ITGB7 3406/4885ALOX5 1527/4885 |
| US-11464796-B2 | Nicotinamide mononucleotide derivatives and their uses | NAMPT, NNT, NQO1 | ITGA4 3379/4885ITGB7 3406/4885ALOX5 1527/4885 |
| US-20140286903-A1 | Substituted Purine Nucleosides, Phosphoramidate and Phosphordiamidate Derivatives for Treatment if Viral Infections | PNP, TYMP, SLC29A1 | ITGA4 2965/4885ITGB7 3563/4885ALOX5 2020/4885 |
| US-12485135-B2 | Nicotinamide mononucleotide derivatives and their uses | NAMPT, NNT, NQO1 | ITGA4 3379/4885ITGB7 3406/4885ALOX5 1527/4885 |
| US-11878027-B2 | Nicotinamide mononucleotide derivatives and their uses | NAMPT, NNT, NQO1 | ITGA4 3379/4885ITGB7 3406/4885ALOX5 1527/4885 |
| US-20240350523-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | NAMPT, NNT, NQO1 | ITGA4 3379/4885ITGB7 3406/4885ALOX5 1527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.